On the Road to Accurate Biomarkers for Cardiometabolic Diseases by Integrating Precision and Gender Medicine Approaches by Scola, L. et al.
 International Journal of 
Molecular Sciences
Review
On the Road to Accurate Biomarkers for
Cardiometabolic Diseases by Integrating Precision
and Gender Medicine Approaches
Letizia Scola 1, Rosa Maria Giarratana 1, Salvatore Torre 2, Vincenzo Argano 2, Domenico Lio 1
and Carmela Rita Balistreri 1,*
1 Department of Biomedicine, Neuroscience and Advanced Diagnostics (Bi.N.D.), University of Palermo,
90134 Palermo, Italy; letizia.scola@unipa.it (L.S.); rosamaria.giarratana@unipa.it (R.M.G.);
domenico.lio@unipa.it (D.L.)
2 Unit of Cardiac Surgery, University of Palermo, 90127 Palermo, Italy; salvotower86@gmail.com (S.T.);
vargano@hotmail.com (V.A.)
* Correspondence: carmelarita.balistreri@unipa.it; Tel.: +39-091-2389-6220
Received: 17 October 2019; Accepted: 27 November 2019; Published: 29 November 2019 
Abstract: The need to facilitate the complex management of cardiometabolic diseases (CMD) has
led to the detection of many biomarkers, however, there are no clear explanations of their role
in the prevention, diagnosis or prognosis of these diseases. Molecules associated with disease
pathways represent valid disease surrogates and well-fitted CMD biomarkers. To address this
challenge, data from multi-omics types (genomics, epigenomics, transcriptomics, proteomics,
metabolomics, microbiomics, and nutrigenomics), from human and animal models, have become
available. However, individual omics types only provide data on a small part of molecules
involved in the complex CMD mechanisms, whereas, here, we propose that their integration
leads to multidimensional data. Such data provide a better understanding of molecules related to
CMD mechanisms and, consequently, increase the possibility of identifying well-fitted biomarkers.
In addition, the application of gender medicine also helps to identify accurate biomarkers according
to gender, facilitating a differential CMD management. Accordingly, the impact of gender differences
in CMD pathophysiology has been widely demonstrated, where gender is referred to the complex
interrelation and integration of sex (as a biological and functional marker of the human body) and
psychological and cultural behavior (due to ethnical, social, and religious background). In this review,
all these aspects are described and discussed, as well as potential limitations and future directions in
this incipient field.
Keywords: cardiometabolic diseases; management; multi-omics integration; gender medicine;
accurate CMD biomarkers
1. Challenges and Drawbacks in the Research of Appropriate Biomarkers for the Management of
Cardiometabolic Diseases
Cardiometabolic diseases (CMD) represent a heterogenous group of diseases, characterized by
difficult management, as well as limited prediction, based essentially on classical risk factors
because accurate molecular predictors are lacking [1,2]. Therefore, the search for appropriate
biomarkers with diverse applications from risk prediction and screening to diagnosis and prognosis,
and the creation of specific algorithms useful in preclinical and clinical settings are encouraged.
To date, different biomarkers have emerged in the literature. For example, the interesting data
obtained from different studies on the role of some circulating molecules, such as C-reactive
protein (CRP) [3–5], adiponectin [6–8], leptin [9–13], in quantifying the CMD risk, have failed
Int. J. Mol. Sci. 2019, 20, 6015; doi:10.3390/ijms20236015 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2019, 20, 6015 2 of 19
to identify promising biomarkers for CMD prevention. Indeed, they have not been confirmed
in large meta-analyses or by using an association’s analyses (i.e., Mendelian randomization
analyses) [3–13]. Nevertheless, novel biomarkers continue to be suggested by CMD research groups
which include: inflammasome molecules [14,15], cardiac fibrosis markers [16], apelin [17], cytokines [2],
metabolites [18], and microRNAs [19–21], etc. However, their biological role in CMD reduction,
diagnosis, or prognosis remains to be elucidated. Such research appears difficult, because several steps
in the investigations are required, which include: (a) assessing associations with preclinical and clinical
phases of CMD, (b) confirming their replication in numerous studies, and (c) testing their effective clinal
utility before affirming any definitive statement on their potential relevance in clinal CMD management.
In addition, combinations of biomarkers and panels of biomarkers, rather than a single biomarker,
are required to improve CMD prediction, diagnosis, and prognosis by creating algorithms. Studies on
the therapeutic effects of potential biomarkers could also be promising. However, such investigations
generally show numerous limitations, essentially linked to high biological (i.e., sex, age, and genetic
background, ethnicity, epigenetics, microbiome and environmental factors) and methodological
variability. Moreover, biomarker appraisal in large population study results are more difficult,
because the biomarkers identified may be the result of diverse pathophysiological processes,
and therefore it is crucial to evaluate the reliability, validity, sensitivity, specificity, ascertainment
bias, and the analysis of data. Consequently, any potential confounding factors need to be revealed
that in the are not easy to recognize in the major part of such studies. From recent studies, the emerging
biomarkers that are not well investigated in the population’s research are of interest. Indeed, they are
affected by the multiethnic origins of the populations studied, the diverse pathophysiological conditions
of individuals enrolled, sex and gender discrepancy, and diverse experimental conditions in the human
and animal models used. Additionally, Mendelian randomization analysis on polymorphisms in
biomarker genes is suggested for assessing the link of the potential associations with CMD risk and
biological relationships. The omics biomarkers, whose relevance remains to be determined, are another
important aspect recently suggested by the precision medicine studies. Omics biomarkers have
been derived from studies based on unstandardized protocols for sample collection, storage and use.
Thus, all such mentioned studies have not used standardized methodologies and, until now, no clinical
trials have been planned to evaluate the effectiveness of the large list of biomarkers discovered [22,23].
All these observations suggest that further scientific efforts are needed for the identification
of appropriate biomarkers for CMD. To this aim, further advances may be achieved by
studying, through a new technological appraisal based on innovative approaches and systems,
molecules associated with disease pathways that can represent valid disease surrogates. In order to
achieve this goal, in this review, we emphasize the necessity to integrate multi-omics analyses,
by combining up-to-date common investigations on genomics, epigenomics, transcriptomics,
and proteomic profiles, with the recent metabolomics, microbiomics, and nutrigenomics investigations.
Accordingly, some biomarkers identified as a result of these investigations are reported as examples.
We also underline the importance of including, in these investigations, high-throughput technologies
and innovative three-dimensional (3D) and four-dimensional (4D) systems for a deep knowledge
of the molecular framework of CMD and, consequently, for identifying well-fitted biomarkers.
Particular attention is also given to the discussion of the relevance of sex dimorphism, as a major
challenge in the identification of accurate biomarkers, as well as in the CMD differential management
and therapies. In addition, other confounding factors are considered, such as age and medication
(Figure 1). Finally, we describe some gaps in these approaches, as well as potential limitations and
future directions in this emerging field.
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2. Multi-Omics Approaches, 3D and 4D Systems, and Innovative Techniques to Search for more 
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The importance of genetics to the onset of CMD is well recognized [14] but environmental factors 
[24] play a crucial role in defining the degree of genetic susceptibility to CMD that occurs. Continuous 
environmental exposures modulate the CMD risk [24], and diet is one of the most crucial [24,25]. 
Smoking represents another important modifiable risk factor, but advances in the conspicuous 
decrease of smoking rates have been achieved in several Western populations [24,26]. For example, 
in the United States the decrease has been significant and, consequently, there has been a reduction 
in CMD cases since the 1960s [26]. However, another relevant risk factor is that obesity related to diet 
has increased after a decrease in smoking percentages [24]. Thus, diet is both a crucial and directly 
modifiable risk factor [24,25]. This indicates that a better understanding of healthy nutrition can 
augment quality of life and decrease worldwide disease morbidity and mortality [27,28]. For 
example, diverse studies and recent meta-analyses have reported the crucial role of a Mediterranean 
diet in reducing the risk of chronic diseases, such as CMD, and improving life quality [28–33]. In 
addition, the key role of microbiome in CMD onset has also been demonstrated, as well as the 
interaction between diet and gut microbiota and CMD [34,35]. An altered diet, consequently, 
modifies the composition of gut microbiota, referred to as dysbiosis, which is significantly associated 
with CMD, including atherosclerosis, hypertension, heart failure, chronic kidney disease, obesity, 
and type 2 diabetes mellitus. In addition to these changes, altered metabolism of gut microbiota has 
also been shown to contribute to CMD development [28,34,35]. 
This recent evidence has motivated CMD researchers to perform not only genetic studies, but 
also other omics investigations, including the analysis of the transcriptome, epigenome, proteome, 
and more recently, the evaluation of metabolome, microbiome, nutrigenomics, etc. However, the 
current omics studies on CMD have focused on individual omics types that have provided data on a 
small part of the molecules involved in the complex CMD mechanisms, whereas the solution could 
be derived from their integration that could lead to obtaining multidimensional data. Such data could 
provide a better understanding of the molecules related to CMD mechanisms and, consequently, 
increase the possibility of identifying well-fitted biomarkers [36]. This could also facilitate their 
complex management and therapy, the most important objectives of clinical community. Certainly, 
the use of more appropriate study models, such as the innovative three-dimensional (3D) 
cardiometabolic tissue constructs, can help in the integration of multi-omics approaches [37,38] (see 
Figure 2). The 3D systems attempt to address limitations of the conventional two-dimensional (2D) 
in vitro models, such as monoculture cellular assays, as well as in vivo animal models [37–39]. The 
2D in vitro models have limitations in the simulation of CMD pathophysiology because of the high 
degree of complexity in the structure and function of the cardiometabolic tissues [37,38]. Precisely, 
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2. Multi-Omics Approaches, 3D and 4D Systems, and Innovative Techniques to Search for More
Appropriate CMD Biomarkers: Reasons, Gaps, and Limitations
The importance of genetic to the onset of CMD is well recognized [14] but environmental
factors [24] play a crucial role in defining the degree of genetic susceptibility to CMD that occurs.
Continuous environmental exposures modulate the CMD risk [24], and diet is one of the most
crucial [24,25]. Smoking represents another important modifiable risk factor, but advances in the
conspicuous d c ase of smoking rates have been achieved in several Western populations [24,26].
For exampl , in the United States th de reas has be n significant and, c sequently, there has been
a reduction in CMD cases since the 1960s [26]. However, another relevant risk factor is that besity
related to diet has increased after a decrease in smoking percentages [24]. Thus, diet is both a crucial and
directly modifiable risk factor [24,25]. This indicates that a better understanding of healthy nutrition can
augment quality of life and decrease worldwide disease morbidity and mortality [27,28]. For example,
diverse studies and recent meta-analyses have reported the crucial role of a Mediterranean diet in
reducing the risk of chronic diseases, such as CMD, and improving life quality [28–33]. In addition,
the key role of microbiome in CMD onset has also been demonstrated, as well as the interaction
between diet and gut m crobiota and CMD [34,35]. An altered diet, consequently, modifies the
composition of gut microbiota, referred t s dysbiosis, which is significantly associated with CMD,
including atherosclerosis, hypertension, heart failure, chronic kidney disease, obesity, and type 2
diabetes mellitus. In addition to these changes, altered metabolism of gut microbiota has also been
shown to contribute to CMD development [28,34,35].
This recent evidence has motivated CMD researchers to perform not only genetic
studies, but also other omics investigations, including the analysis of the transcriptome,
epigenome, proteome, and more recently, the evaluation of metabolome, microbiome, nutrigenomics,
etc. However, the current omics studies on CMD have focused on individual omics types that have
provide data on a small part of the molec les involved the complex CMD mechanisms, whereas the
solution could be derived from their integration that could lead to obtaini g multidimensional
data. Such data could provide a better understanding of the molecules related to CMD mechanisms
and, consequently, increase the possibility of identifying well-fitted biomarkers [36]. This could also
facilitate their complex management and therapy, the most important objectives of clinical community.
Certainly, the use of more appropriate study models, such as the innovative three-dimensional (3D)
cardiometabolic tissue constructs, can help in the integration of multi-omics approaches [37,38] (see
Figure 2). The 3D systems attempt to address limitations of the conventional two-dimensional
(2D) in vitro models, such as monoculture cellular assays, as well as in vivo animal models [37–39].
The 2D in vitro models have limitations in the simulation of CMD pathophysiology because of
the high degree of complexity in the structure and function of the cardiometabolic tissues [37,38].
Precisely, these analyses are unable to summarize the complex cell-extracellular matrix (ECM),
cell–cell, and tissue-level interactions. To address the limitations of 2D assays, animal (e.g., mouse)
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models have been used, because they mimic the complicated tissue-level representation. But such
investigations have led to the awareness of numerous differences between mouse models and human
disease [40,41]. Currently, several techniques for creating 3D cardiometabolic tissue models have
been proposed. In addition, recently, in vitro research has also suggested the use of human-derived
cardiac-metabolic cells in 3D systems, derived from methods for cardiometabolic differentiation
of human stem cells in order to generate patient-specific and genetically edited cardiometabolic
cells [42]. Specifically, recently, human induced pluripotent stem cells (iPSCs) have also been used
as an attractive approach for overcoming the above-mentioned limitations of animal models,
creating a more appropriate CMD model and enabling discovery drugs [43]. This is strongly linked
to their features. The iPSCs not only have the capacity for self-renewal and differentiation but
can also be directly produced from the patients’ skin fibroblasts, blood cells, and other somatic cell
sources. Consequently, patient-specific iPSCs could provide a source of unlimited disease-relevant
cells in a personalized manner, including cardiomyocytes, which have been previously inaccessible.
However, to use iPSCs, their genome instability, epigenetic memory associated with the reprogramming
process [28,44], and their maintenance represent important limitations to their effective application.
Indeed, these factors exemplify the very issues in achieving the integrity of iPSC cellular derivatives
and creating accurate models of diseases [43]. In addition, iPSCs are commonly used in 2D monolayers
to discover disease phenotypes, however, the 2D systems do not reproduce the tissue- and
organ-level structures and functions. This has led to the development of 3D iPSC models that
can more accurately reproduce tissue- and organ-level disease pathophysiology (see Figure 2).
Furthermore, innovative biomaterials, as well as micro- and nanoscale technologies can be used
as components of 3D systems that enhance the functionality of engineered cardiometabolic tissues
through an accurate control on cell–cell and cell-ECM interactions [37,38]. The 3D micro-engineered
cardiometabolic tissue models have been successfully utilized to better understand the biological basis
of CMD progression and to increase the effectiveness of pharmaceutical testing of candidate therapeutics
to help prevent or reverse CMD [37,38]. The above-mentioned 3D systems show some limitations for
studying both ontogenesis and disease progression because they are intrinsically dynamic processes
with cellular and tissue-level biological activities altered not only spatially, but also temporally [45].
Currently, the 3D existing systems principally reproduce spatial events in a single organ and fail to show
associated temporal events, including the progression of organ development, ageing, the dynamics
of tissue healing and regeneration, the exchange of metabolites between organs, and the sequential
pathogenesis of inflammation, infection and multi-organ failure [45]. Thus, further advances in
the reproduction of temporal events in the existing 3D models are encouraged. As an alternative
technology, organ-on-chip technology can include various patient-specific iPSC-derived 3D constructs
in a dynamic system, creating a 4D multi-organ system, also known as “body-on-chip”, via a circulating
flow that mimics the systemic interactions among different tissues and organs (Figure 2). The 4D
multi-organ systems can also have in-line sensors and fluorescent reporters for the real-time
quantification and analysis of cellular dynamics during a disease study. The 4D multi-organ systems are,
however, in the early developmental phases. Currently, they have been used to study the adsorption,
distribution, metabolism, elimination, and toxicity of drugs [46–48]. Recently, a proof-of-principle
system comprising intestine, skin, liver, and kidney chips has been developed, although it was only
maintained for more than four weeks [49]. In the future, 4D multi-organ systems are expected
to be further improved by integrating with different 3D platforms to create efficiently engineered
organoid-on-chips. These could be maintained in a physiological environment produced by integrated
engineered organoids for extended periods of time to enable the temporal investigation of dynamic
disease pathogenesis.
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fatty acids, acylcarnitines, and other metabolites with CMD. For example, targeted metabolomics has 
discovered a signature of dysregulated metabolism of branched-chain amino acids (BCAA) in 
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Figure 2. The study of cardiometabolic pathologies and the search for relative biomarkers have
constantly evolved. After the two-dimensional systems constituted by monolayer cells, the so-called
three-dimensional systems that combine the use of cardiomyocytes derived from the patient’s committed
stem cells with artificial platforms and biosensors have been developed. The next goal is the
standardization of 4D microchip systems that mimic the complexity of multi-organ interactions.
Other technologies have been added to 3D systems to improve their effectiveness, such as
gene-editing techniques. Among the most recent, clustered regularly interspaced short palindromic
repeats-associated protein 9 (CRISPR/C s9) and chemically modified RNA technique, have also been
i corporated in 3D models in order to study related p thologies or potential dis ase correctio
through r storation [50]. For example, CRISPR-Cas9 technology allows si le nucleotides to b
edited with high preci ion in the endogenous gen me, opening up the possibility of producing
mous models harboring identical gene variants to those ide tified by genome-wide association
studie (GWAS), in humans. This is shown by studies on obesity-associated genes, where th
rs1421085 T-t -C single nucleotide polymorphism has been fo nd to favor the switch of BAT
to WAT adip se tissue, reducing mitoc ondrial thermogenesis an increasing lipid storage. The
CRISPR-Cas9 replication of the T-to-C in the quivalent primary di ocytes from a non-risk allele
carrier has simulated this switch [51]. Other studies have also combined iPSCs and CRISPR/Cas9
technology to inv stigate the molecular and cellular mechanisms underlying inherit d CMD [52].
Through the t chnologies, therefore, there is a belief that CMD gen tical modeling could pr sper. In
additi n, CMD res arch rs are also planning to includ CRISPR/Cas9 assay in the final step of a deep
investigation that, first, includes GWAS, which is able to identify novel genetic loci associated with
CMD risk in diverse populations, and omics profiling (transcriptomics, proteomics, metabolomics, and
microbiomics) studies, to translate genetic and molecular findings for clinical applications through the
identification of appropriate biomarker panels, and for treatment of both rare and common CMD [53]
(see Figure 2).
2.1. A Focus on Metabolomics and Metabolite Profiling and Examples of Related CMD Biomarkers
The tradition current omics analyses (i.e., transcriptomics, epigenomics and proteomics
investigations), as well as the emerging metabolomics analyses for predictions are needed to obtain
multidimensional results on CMD. Metabolomics represents the profiling of small molecule metabolites
in biofluids, cells and tissues, or whole organisms [18]. During the past two decades, it has been
the focus of a rapid technological evolution (i.e., magnetic resonance and various types of mass
spectrometry) [18]. Such innovation has led to the application of metabolomics to define predictive
biomarkers for CMD, and increasingly, as a blueprint for understanding their pathophysiologic
mechanisms [18,54]. Thus, some studies have tested the associations of amino acids, fatty acids,
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acylcarnitines, and other metabolites with CMD. For example, targeted metabolomics has discovered
a signature of dysregulated metabolism of branched-chain amino acids (BCAA) in patients with
different CMD [40]. The BCAAs, including leucine (Leu), isoleucine (Ile), and valine (Val) have several
functions which include: (a) they are involved in synthesis of nitrogenous compounds; (b) they are
also signaling molecules able to regulate glucose and lipid metabolism, as well as protein synthesis;
and (c) they also contribute to the regulation of intestinal health and gut immunity interacting with
a signaling network, precisely represented by phosphoinositide 3-kinase/protein kinase B/mammalian
target of rapamycin (PI3K/AKT/mTOR) signal pathway [55].
The established data on the significant relationship of BCAAs and their derivatives with CMD
suggest that they are potential biomarkers. Furthermore, based on this link we infer that adjusting
dietary BCAA levels could have beneficial effects on the parameters related to the reduction of CMD
risk (Figure 3).
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Figure 3. Branched-chain amino acids (BCAAs) as a novel diagnostic and prognostic metabolites
of cardiometabolic diseases (CMD). The BCAAs are essential amino acids that are not synthesized
in our body. Thus, they need to be obtained from food or produced by gut microbiota. At the
level of peripheral tissues, mainly in muscle and adipose tissue, in the mitochondria BCAAs are
catabolized. The first step is a transamination reaction performed by the mitochondrial isoform
of branched-chain amino acid transaminase (BCTm). Then, the are oxidiz d by the multienzyme
mitochondrial branched-chain-ketoacid dehydrogenase complex (BCKDC), that transforms the BCCAs
into its relative ketoacids, energy substrates for the synthesis of sugars, proteins, and lipids. An alteration
into the catabolic pathway det rmines an ac umulati t e circulation, inducing the
activation f the network of phosphoinositide 3-kinase/protein kinase B/m mmalian target of r pamycin
(PI3K/AKT/mTOR) signal pathways.
Moreover, ec nt evidence has also t that small metabolites are associated with
a negative prognosis . This is the case for the metabolites of the nitric oxide (NO) pathway
that show alterations in CMD patients complicated with chronic wounds of the lower extremities [56].
However, the full potential of metabolomics for identifying appropriate biomarkers remains to be
realized. It is hoped that this interest will encourage more investigations focused on metabolomics in
CMD research, and more specifically, on disease-associated metabolomic signatures for discovering
novel CMD biomarkers and targets.
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Other important data have been provided from lipidomics studies [57], since CMD exhibit
changes in lipid biology. Indeed, lipid imbalance is closely associated with CMD, such as
atherosclerosis, obesity, diabetes, and Alzheimer’s disease. Lipidomics or lipid profiling is
a lipid-targeted metabolomics approach based on a complete analysis of lipids in biological systems [58].
Several distinct metabolic pathways potentially involved in lipoprotein metabolism in both healthy
and disease states (obesity, insulin resistance, and fatty liver disease), as well as under lifestyle
and dietary modification (fish consumption, carbohydrates, and probiotics) and lipid-modifying
treatments (statins and low-density lipoprotein apheresis) have been recently discovered. In addition,
a detailed characterization of lipid classes and molecular species present in plasma, as well as
in lipoprotein fractions, has been recently obtained [57,58]. This suggests that lipidomics (for
example, plasma lipoprotein) analysis together with other omics investigations, such as metabolomics,
have enabled obtaining molecular specifics of the lipoprotein composition, which can be translated
into an integrated knowledge of the structure, metabolism, and function of lipoproteins in CMD,
and consequently, into appropriate biomarkers.
2.2. Microbiomic Profiling and Related Promising CMB Predictive Biomarker
Gut microbiota has been recently associated with CMD through a direct action on gut immunity or
altering blood levels of bioactive metabolites [59]. Accordingly, data obtained by two research
groups [60,61] have demonstrated that circulating levels of trimethylamine N-oxide (TMAO),
a metabolite of the gut microbiota, are CMD predictors. TMAO is a small organic compound,
predominantly obtained from choline (found in foods such as red meat, fish, poultry, and eggs),
metabolized by microbiota to trimethylamine (TMA), and, then, to TMAO for action of the hepatic
enzyme, flavin monooxygenase 3 [62,63]. Further studies have investigated this association obtaining
contrasting data. However, recent meta-analyses have reported that elevated circulating levels of
TMAO and its precursors are significantly associated with increased risk of CMD, independently of
traditional risk factors [62,63] (Figure 4).
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TMAO is a metabolite derived from a diet rich in fats which is metabolized to produce trimethylamine
(TMA) by microbiota. The figure shows a possible mechanism for the inhibition of TMA formation by
blocking the pair of microbial enzymes, Cut C/D, responsible for the transformation of choline into
TMA. Trimethylamine, TMA; flavin monooxygena O; and trimethylamine n-oxide, TMAO.
Nevertheless, further studies are necess r t confirm these promising data and the role of
TMAO, even if it has been reported that it mediates modifications in cholesterol (reductions in
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reverse cholesterol transport) and sterol metabolism, as well as in bile acid pool size and composition,
and increases platelet hyperreactivity and thrombosis risk [64].
2.3. Nutrigenomics and Nutrigenetics Approaches in the Research of CMD Biomarkers
Given the relevance of diet in modulating the CMD risk, the application of nutrigenomics and
nutrigenetics approaches are fundamental, first, to understand the interaction between the metabolic
processes and the environment’s effects in CMD processes, and, secondly, to identify molecules that
have key implications in CMD prevention and treatment. Accordingly, nutrigenomics and nutrigenetics,
like pharmacogenomics, can detect genetic predictors of CMD-relevant responses to diet, to be applied
both as potential preventive biomarkers and targets for therapeutic interventions [24]. This could
also favor the inclusion of nutrigenomics and nutrigenetics in the context of personalized nutrition.
However, nutrigenomics and nutrigenetics have also been the focus of intricate investigations and
false promises, which, until now, have failed to demonstrate their potential. Despite this, the American
Heart Association is strongly affirming the significant relationship existing among nutrigenomics and
nutrigenetics, microbiome, and gene–environment interactions and their influence on CMD onset and
progression [24]. Furthermore, diverse trials have been performed to investigate the potential of dietary
pattern to stop hypertension and prevent CMD such as diabetes and cardiovascular diseases [24].
Among these, the PREDIMED trial, “Primary prevention of cardiovascular disease with Mediterranean
diets” demonstrated that the Mediterranean diet is helpful, because it reduces the incidence of
numerous major chronic diseases in individuals at high cardiovascular risk, and it mainly includes
the consumption of extra virgin olive oil [65]. These promising data have led to research genes and
polymorphisms involved in the gene–nutrient interaction through epigenetic factors, and interesting
data have been obtained. However, the discoveries of nutrigenomics and nutrigenetics cannot be
rigorously applied to CMD prevention and treatment, at this time, and the crucial results currently
obtained, or in via of being produced, can only be used as a basis for enhancing the reliability of
imminent research.
2.4. The Difficult Challenge of Integration and Interpretation of Multidimensional Data from
Multi-Omics Analyses
Data obtained from the combination of multi-omics analyses can be integrated to obtain complete
information from several molecular areas that could be translated into a better understanding
of underlying mechanisms involved in CMD pathogenesis and the selection of biomarkers with
diagnostic or prognostic values. [66]. This first implies a phase of data preprocessing to evaluate
quality control and data normalization. Correct preprocessing is crucial to eliminate outliers and
nonbiological variation within a data type and increase the biological comparability between data types.
Currently, multidimensional data integration tools have been developed and could be selected from
the following five distinct categories: clustering and dimensionality reduction-based methodologies,
predictive modeling approaches, pairwise integration, network-based methodologies, and composite
approaches. They are mainly created for specific combinations of data types. Their selection requires
consideration of data-driven statistical patterns and biological interpretability. However, depending
on the specific applications, the significance of these two aspects may vary. Therefore, before
choosing an appropriate method, it is imperative to, first, understand the biological question that
is being addressed, i.e., biomarker discovery or mechanistic insight. For the discovery of diagnostic
and prognostic biomarkers, data pattern is the key factor, whereas biological interpretation can be
less important.
Nevertheless, this field is still in its early stages, and the flexibility, effectiveness, and robustness
of data integration to obtain biological insights are still limited. The limitations are principally
due to the intrinsic complexity within individual datasets and between datasets, as well as
technical difficulties in integrative modeling that accurately captures true biological complexity.
Furthermore, the performance of the various methodologies has not been exhaustively compared,
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and there is a lack of general guidance in the field on best practices. To address these
challenges, future efforts should focus on intimate collaborations among computational biologists,
systems biologists, and experimental biologists in the following areas described below.
3. Adding Another Important Layer: Sex Dimorphism in CMD and its Relevance in the Research
of Accurate Sex or Gender Biomarkers
Another important challenge in cardiometabolic research is sex dimorphism. Women and
men differ not only in their anatomy and physiology, but also in more complex traits. We have
recently observed these differences in lifespan (in Italy, 78.8 years for men and 84.1 years for women,
respectively) [67], mortality [68], age-related diseases pathophysiology, onset, and progression [69],
and immune and inflammatory responses and age-related immune and inflammatory disorders [68,69].
Recently, the sex-specific predominance of common types of CMD has also been observed.
Precisely, women (and particularly women affected by diabetes) as compared with men have higher
risk for heart failure, atrial fibrillation, and ischemic heart disease, even if the identification of these
differences and the underlying mechanisms is only just emerging. Some studies suggest that sex
hormones, sex-specific molecular mechanisms, and gender influence glucose and lipid metabolisms,
as well as cardiac energy metabolism, and function [70]. Accordingly, Lusis et al. [71] have largely
stressed sex differences in metabolic and cardiovascular traits, evidencing differences in body fat
distribution, glucose homeostasis, insulin signaling, ectopic fat accumulation, and lipid metabolism
during normal growth and in response to hormonal or nutritional imbalance. They have also
affirmed that these differences can partly be mediated through sex hormones and the sex chromosome
complement [71]. In addition, an intricate interaction between environmental, social structural,
behavioral (i.e., the complex pattern of roles and values that define what is thought as “masculine” and
“feminine”) and genetic factors have been also proposed as probable explanation [70]. Our group have
underlined that diverse genetic, epigenetic, hormonal factors, and different cellular and molecular
signaling pathways are implicated in the diverse sex-specific effects in women related to onset and
progression of CMD [72] (see Figure 5). The group of Razavi has recently reported that whereas
modest differences characterize the gut microbiome composition of women as compared with men,
there appears to be strong effects of gut microbiome-dependent metabolites in females as compared
with males [73] (see Figure 5). Accordingly, microbiome-associated TLR signaling pathways, bile acid
metabolism, and steroid hormone modulation have been demonstrated to be the crucial drivers in
sex differences in CMD risk. However, additional studies are imperative to explain the role of these
pathways and to define their role as biomarkers and therapeutic targets (see Figure 5).
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Figure 5. Sex differences are mediated through reversible sex hormones. Various metabolites of
the microbiome can e diff rent influences in the two genders. ACE, a giotensin converting
enzyme; BCAA, branched-chai amino acid; PPRA-γ, peroxisome proliferator activator receptor-γ;
SAT, subcutaneous adipose tissue; SCFA, short-chain fatty acid; SREBEP1, sterol regulatory-binding
protein TLR; TLR, toll-like receptors; VCA, visceral adipose tissue.
The evidence reported above infers suggesting the requirement of applying in women, as compared
to men, diverse biomarker’s panels for CMD diagnosis, prevention, and prognosis. This finding
is supported in the evidence of emerging literature. Schiebinger and coworkers. have elegantly
emphasized these differences and suggested that sex and gender analysis need to be incorporated into
the experimental design. This can enable advancements, such as improved treatment and differential
management of CMD and insights into the societal impact of algorithmic bias [74].
4. Age and Medication: Other Factors to Consider in the Search of CMD Biomarkers and
Strategies for Reducing their Effects
In studying diseases, such as CMD, we are often forced, by timing, economics, or ethics, to use
not perfect experimental designs. This determines various interpretational problems, including the
issue of confounding [75]. Confounding defines a situation in which the result is biased because
of the differences between compared groups, such as baseline characteristics, prognostic factors,
or concomitant interventions. For a factor to be a confounder, it must differ between the comparison
groups and predict the outcome of interest. Confounding is, thereby, fundamental to the design,
analysis, and interpretation of studies intended to estimate causal effects. This implies performing
an appropriate selection of the populations in an investigation [75]. Precisely, this leads to considering
no explicit differences (imbalances) between the populations included in a study with respect to
circumstances or covariates that could affect the association of cause and effect. Covariates represent
the confounders in a study. In the context of CMD studies, age and medication are valid confounders.
For example, Wike and coworkers demonstrated that clinical and echocardiographic manifestation of
aorta stenosis are age dependent [76]. We have largely shown in our studies on age-related diseases,
such as CMD, how age can significantly affect the results obtained [77]. Age modulates any mechanism,
activity, phenotype of cells [77], influencing for example the circulating lipidic [78] and protein profile,
the levels of glucose, hormones, activity of microbiome and their metabolites, inflammatory and
immune profile [79], and architecture and function of organs and systems [80]. Given its relevance it is
imperative to consider this factor in selecting the population studied.
Concerning therapeutic treatments, it has been demonstrated by clinical trials with statins,
β-blockers, and antihypertensive agents that individuals with poor persistence had worse outcomes
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than did persistent individuals [81,82]. Another study has evidenced that the activity of crucial
pathways related to heart functionality are modulated by drugs. It has also been reported that the
combined use of aspirin, a statin, and blood pressure lowering agents (polypill components) reduces
the risk of vascular morbidity and mortality in patients with coronary artery disease [83].
These observations have motivated researchers to search for important recommendations to resolve
this issue that could affect the search of accurate CMD biomarkers. For example, Howards [84,85]
has recently recommended that an initial strategy might be design phase restriction, that consists of
including a specific category of a confounder (e.g., male or female people); secondly, matching of
controls to cases to enhance equal representation of subjects with certain confounders among study
groups; then, performing analytical phase stratification, where the sample is divided into subgroups or
strata on the basis of characteristics that are potentially confounding the analysis (e.g., age). To this
point, it recommends performing a statistical adjustments regression for estimating the association of
each independent variable with the dependent variable (the outcome) after adjusting for the effects of
other variables. It can also consider the propensity score, which is a score given by the conditional
probability of exposure to an intervention linked to a set of observed variables that may influence the
likelihood of exposure. It also recommends including the instrumental variable, which represents
a pseudo-randomization method. It divides patients according to levels of a covariate that is associated
with the exposure but not associated with the outcome.
5. Another Revolutionary Approach to Consider in CMD Biomarkers Research:
Extracellular Vesicles
Extracellular micro- and nanoscale membrane vesicles are produced by different cells
and are attracting the attention of the scientific community. They act as mediators of
intercellular communication and transport genetic material and signaling molecules to the cells.
Accordingly, extracellular vesicle (EV) is comprised of not only membrane proteins and lipids from the
cell surface, but also nucleic acids (DNA and RNA) including mRNAs, microRNAs, small-interfering
RNAs, and long non-coding RNAs from the intracellular environment [86,87]. In the context of
keeping homeostasis, the extracellular vesicles contribute to the regulation of various systemic
and local processes. Significant advances have been made regarding the criteria of the following
classification of the vesicles according to their origin, content, and function: Exosomes; microvesicles,
also referred to as microparticles or ectosomes; and large vesicles defined as actively released
vesicles [86,87]. Additionally, apoptotic bodies represented by a highly heterogeneous population
of particles produced during apoptosis, the programmed cell death, also exist. However, a joined
term “extracellular vesicles” (EVs) has been recommended for the definition of vesicles isolated
from either the cell culture supernatants or the body fluids [86,87]. Because the content of
EVs reflects the content of the cell of origin, multiple studies on EVs from body fluids in the
context of disease diagnosis, prediction, and prognosis have been performed, actively supporting
their high potential as a biomarker source. In the CMD studies, EVs related to thrombosis,
inflammation, endothelial dysfunction, or angiogenesis, have been significantly observed in patients
with acute coronary syndrome [88], ST-elevation myocardial infarction [89,90], cardiac remodeling [91],
type 2 diabetic mellitus [92], diabetic retinopathy [93,94], as well as other CMD. They can be identified
in body fluids, including blood, urine, synovial fluid, and many other body fluids, from individuals
affected by various diseases. This suggests that they might represent ideal biomarkers for no invasive
CMD diagnosis and prognosis. However, the true problem in this application is in the development of
reliable and effective methodologies for routine laboratory analysis of EVs, as well as the discovery of
the mechanism involved in the transport of genetic components from the cell environment into the
EVs [95,96]. Consequently, it remains unclear and it is not easy to test EVs in liquid samples, or precisely
in liquid biopsy. Furthermore, another crucial point in this analysis is in obtaining quantitative levels
of genetic contents adapted to be tested, because the number of MVs is very low in the biofluids or they
are loss during sample processing. Another matter is the eventual presence in the biofluids of food
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intake, medications, or other physiological and pathological factors. Thus, optimization of this assay is
imperative, as well as biofluid collection, both of which require further research efforts (Figure 6).
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6. Conclusions and Perspectives
In this review, we propose the integration of multi-omics approaches as a promising tool for the
identification of appropriate biomarkers and therapeutic targets for CMD. This idea has been derived
from the consideration that current omics studies on CMD have only focused on individual omics
types. This represents a limitation in the deep understanding of molecules related to CMD mechanisms,
because the separate omics evaluations enable the discovery of only a part of the CMD-related molecules,
reducing the possibility of identifying well-fitted biomarkers. In addition, a significant number of past
and current omics studies on CMD analyze the transcriptomic, epigenomic and proteomic profiles,
that are currently considered routine. The analysis of metabolomics, microbiomic, and nutrigenomic
profiles are only just now emerging, and are leading to the identification of some promising biomarkers
(some examples have been mentioned above). Executing all the omics analyses in the CMD studies
can certainly imply the detection of well-fitted biomarkers, obtaining data from multidimensional
levels. This could also facilitate the complex management and therapy of CMD, the most important
objective of clinical community. A further help in such research may also be derived from gender
medicine that could add another crucial level in the differential CMD management and therapy
according to gender. Today, gender represents one of the major CMD challenges. Having panels
of appropriate biomarkers for CMD, and for gender, could also facilitate the design of appropriate
algorithms for their prevention, diagnosis, and outcomes, as well as for the development of innovative
guidelines. Certainly, such investigations require an appropriate design for eliminating confounding
factors (e.g., age and medication, see paragraph 4), innovative models (i.e., 3D and 4D systems),
and technologies (e.g., CRISPR/Cas9 and chemically modified RNA technique), as well as (given the
complexity of multidimensional data) integration data tools, such as clustering and dimensionality
reduction-based methodologies, predictive modeling approaches, pairwise integration, network-based
methodologies, and composite approaches.
However, this field of research currently continues to be young, and consequently needs
a major interest and more investigation, based on more accurate, standardized omics techniques.
Nevertheless, the approaches and techniques suggested can give a detailed idea of the information
about which gene, epigenetic factor, protein, pathway, metabolite, microbioma component,
or environmental factor is helpful to consider in the investigation, as well as hypothetically detecting
innovative biomarkers or targets. Cotemporally, this appraisal improves our appreciation versus the
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relevance of CMD pathophysiology in the research, given the rationale of how it may be translated
into appropriate opportunities for clinical utility. Specifically, this investigation enhances our capacity
to predict future CMD, categorize them on a molecular basis for a better diagnostic and prognostic
management, and project personalized therapies tailored to the individual. However, as stressed,
diverse questions remain to be addressed in order to benefit advances in personalized medicine,
but well-designed investigations with the innovative techniques described could certainly support
researchers to overcome them.
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